Travere Therapeutics Financial Results
Travere Therapeutics reported Q3 2026 financial results, highlighted by $200.2 million in FILSPARI net product sales, representing 120% year-over-year growth. The company is advancing its Phase 3 HARMONY study of pegtibatinase with topline results expected in the second half of 2027 and plans to submit an IND for civorebrutinib by year-end.
“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
“As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics